We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

69 hedge funds and large institutions have $35.5M invested in Galectin Therapeutics in 2018 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

50% more capital invested

Capital invested by funds: $23.6M → $35.5M (+$11.8M)

27% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 15

11% more funds holding

Funds holding: 62 → 69 (+7)

0.79% more ownership

Funds ownership: 13.99% → 14.78% (+0.79%)

69% less call options, than puts

Call options by funds: $1.17M | Put options by funds: $3.83M

Holders
69
Holders Change
+7
Holders Change %
+11.29%
% of All Funds
1.58%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
19
Reduced
15
Closed
11
Calls
$1.17M
Puts
$3.83M
Net Calls
-$2.66M
Net Calls Change
-$2.73M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.91M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.48M
3
Group One Trading
Group One Trading
Illinois
+$503K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$368K
5
AG
Advisor Group
Arizona
+$276K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$630K
2
EI
EAM Investors
California
-$491K
3
BCM
BlueCrest Capital Management
Jersey
-$481K
4
DADC
D.A. Davidson & Co
Montana
-$364K
5
EGI
EAM Global Investors
California
-$305K
Name Holding Trade Value Shares
Change 		Change in
Stake
LPL Financial
26
LPL Financial
California
$196K +$35.1K +7,200 +31%
SWP
27
Stratos Wealth Partners
Ohio
$179K – – –
Citadel Advisors
28
Citadel Advisors
Florida
$149K -$215K -44,147 -65%
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$149K – – –
ECM
30
Element Capital Management
New York
$143K +$40.8K +8,376 +59%
CCM
31
Courage Capital Management
Tennessee
$141K -$38.4K -7,874 -26%
ATC
32
Argent Trust Co
Tennessee
$133K +$102K +20,950 New
MML Investors Services
33
MML Investors Services
Massachusetts
$130K +$14.2K +2,917 +17%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$127K -$28.6K -5,878 -23%
WS
35
Wedbush Securities
California
$114K -$87.7K -18,000 -50%
CF
36
Centaurus Financial
California
$106K +$32.7K +6,712 +67%
LWAC
37
Laurel Wealth Advisors (California)
California
$105K -$23.4K -4,800 -22%
Squarepoint
38
Squarepoint
New York
$105K +$80.7K +16,578 New
Jane Street
39
Jane Street
New York
$91K +$70K +14,369 New
SM
40
Sabby Management
Florida
$89K -$630K -129,371 -90%
JA
41
JOYN Advisors
Georgia
$81K – – –
GWM
42
Geneos Wealth Management
Colorado
$78K -$141K -29,040 -70%
RJFSA
43
Raymond James Financial Services Advisors
Florida
$68K +$52.3K +10,733 New
BSW
44
Buckingham Strategic Wealth
Missouri
$64K – – –
DAS
45
Dynamic Advisor Solutions
Arizona
$64K – – –
UBS Group
46
UBS Group
Switzerland
$46K +$5.25K +1,079 +18%
PCM
47
Peak Capital Management
Colorado
$38K +$29.2K +6,000 New
IA
48
IFP Advisors
Florida
$34K +$487 +100 +2%
RWP
49
RWA Wealth Partners
Massachusetts
$29K +$21.9K +4,500 New
SEI Investments
50
SEI Investments
Pennsylvania
$24K – – –
1
2
3 4

GALT Hedge Fund Activity: Q2 2018 in Review

69 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2018, worth a combined $35.5M — up 50% from $23.6M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new GALT positions and 11 closed out — a net gain of 7 holders — while 19 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $1.91M. The largest seller was Sabby Management, cutting an estimated $630K.

  • 69 institutional investors held Galectin Therapeutics (GALT) as of Q2 2018, up from 62 in Q1 2018.
  • Funds reported $35.5M of Galectin Therapeutics stock for Q2 2018, up 50% quarter-over-quarter.
  • 18 funds opened new Galectin Therapeutics positions in Q2 2018 and 11 closed out, a net change of +7 holders.
  • The largest Galectin Therapeutics buyer in Q2 2018 was BlackRock, an estimated $1.91M added.
  • The largest Galectin Therapeutics seller in Q2 2018 was Sabby Management, an estimated $630K sold.

Based on aggregated 13F filings for Q2 2018.